Back to Search
Start Over
Anti-Mycobacterium abscessus activity of tuberculosis F-ATP synthase inhibitor GaMF1
- Source :
- Antimicrob Agents Chemother
- Publication Year :
- 2022
-
Abstract
- New drug targets and molecules with bactericidal activity are needed against the respiratory mycobacterial pathogen Mycobacterium abscessus (Mab). Employing a lead repurposing strategy, the anti-tuberculosis compound GaMF1 was tested against Mab. Whole cell- and ATP synthesis assays demonstrated that GaMF1 inhibits growth and kills Mab by targeting the F-ATP synthase. GaMF1’s anti-Mab activity increased in combination with clofazimine, rifabutin or amikacin The study expands the repertoire of anti-Mab compounds targeting oxidative phosphorylation. National Research Foundation (NRF) Submitted/Accepted version This work was supported by the National Research Foundation (NRF) Singapore, NRF Competitive Research Programme (CRP), Grant Award Number NRF–CRP18–2017–01.
- Subjects :
- Pharmacology
Multi Drug Resistance
Mycobacterium abscessus
Chemistry::Biochemistry [Science]
Mycobacterium Infections, Nontuberculous
F-ATP Synthase
Nontuberculous Mycobacteria
Microbial Sensitivity Tests
Bioenergetics
Anti-Bacterial Agents
Adenosine Triphosphate
Infectious Diseases
Humans
Tuberculosis
Pharmacology (medical)
Enzyme Inhibitors
Mechanisms of Action: Physiological Effects
Mycobacterium Abscessus
γ Subunit Inhibitor
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Journal :
- Antimicrob Agents Chemother
- Accession number :
- edsair.doi.dedup.....ff84cfd6bc512b51920af1dac52a708d